Specificity of CEP:
Full dossier sent directly by manufacturer to EDQM;
Single evaluation centralised at EDQM;
By assessors nominated by national authorities and approved by Certification Steering Committee;
Independent from marketing authorization applications for medicinal products;
Certificate including annexes (additional tests to be performed) granted to manufacturer who supplies a copy of it to its customers (the users of the API/excipient)
CEP程序特征:
全部申报资料由原料药生产商直接递交给EDQM;
EDQM进行单独集中评价;
由各国官方提名,认证管理委员会批准的评估人员进行评审;
独立于药品上市申请;
原料药生产商获得的证书包括附件(待实施的额外检测),原料药生产商可将副本给其客户(原料药/辅料用户)。
3. Advantages of the CEP:
Easier management of regulatory documentation for API manufacturer (no open part);
Savings of time and resources;
Easier management of MAA---replaces main part of 3.2.S;
CEP accepted in all Ph.Eur. Member states (36) + others (eg. Canada, Australia, Morocco, Ner Zealand etc.).
3.CEP证书优点:
原料药生产商比较容易管理药政文件(无公开部分);
节省时间与资源;
比较容易管理上市许可---替代3.2.S主要部分;
所有欧洲药典成员国(36)+其它国家(例如,加拿大、澳大利亚、摩洛哥、新西兰,等)都接受CEP。